SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001615774-17-005829
Filing Date
2017-10-20
Accepted
2017-10-20 16:59:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13D/A s107814_sc13da.htm SC 13D/A 24849
  Complete submission text file 0001615774-17-005829.txt   26300
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89137 | Film No.: 171147488
SIC: 2834 Pharmaceutical Preparations

Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 (650) 688-0822
VIVO VENTURES VII, LLC (Filed by) CIK: 0001565020 (see all company filings)

IRS No.: 274484686 | State of Incorp.: CA
Type: SC 13D/A